Skip to content
PICO Portalanswers from OpenAlex

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

PaperCitations, authors & open-access status

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC is a paper indexed in PICO Portal from OpenAlex.

How many citations does Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC have?

PICO Portalcitation count

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC has 435 citations in the OpenAlex counts PICO Portal stores.

When was Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC published?

PICO Portalyear

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC has 2019 year in the PICO Portal index.

What is the open-access status of Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC?

PICO Portaloa status

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC has hybrid oa status in the PICO Portal index.

What is the DOI of Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC?

PICO Portaldoi

The DOI for Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC is on the source record.

What is the PMID of Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC?

PICO Portalpmid

The PMID for Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC is on the source record.

What is the OpenAlex record for Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC?

PICO Portalopenalex

The OpenAlex for Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial